(Q37962701)

26 August 2017

title

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies (English)

1 reference

26 August 2017

1 reference

Antonio Gualberto

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

30 November 2011

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

205-216

1 reference

State-of-the-art therapeutics: Hodgkin's lymphoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Advances in biology, diagnostics, and treatment of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Anaplastic large-cell lymphoma, T-/null-cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Aggressive peripheral T-cell lymphomas (specified and unspecified types).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Prognosis and primary therapy in peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

The role of CD30 in the pathogenesis of haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Hodgkin's lymphoma and CD30 signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

MicroRNA expression in maturing murine megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

Mechanisms of cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.641532

10.1517/13543784.2011.641532

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference